A randomised multicentre accelerated radiotherapy study of dose escalated intensity modulated radiotherapy versus standard dose intensity modulated radiotherapy in patients receiving treatment for locally advanced laryngeal and hypopharyngeal cancers

Royal Marsden NHS Foundation Trust (UK)0 个研究点目标入组 276 人开始时间: 2011年3月31日最近更新: 2022年4月4日

适应症

试验速览

2021 Results article in https://pubmed.ncbi.nlm.nih.gov/34256319/ (added 14/07/2021)

•1. Aged 16 years or above, either sex
•2. Histologically confirmed squamous cell cancer of the larynx or hypopharynx
•3. Chemo-radiotherapy is the investigators treatment of choice. Induction chemotherapy is permitted.
•4. Locally advanced squamous cell cancer of the larynx or hypopharynx i.e. stage III or IV a/b disease
•5. World Health Organization (WHO) performance status of 0 or 1
•6. Creatinine clearance of greater than 50 ml/min
•7. Must be suitable to attend long term follow-up. All patients participating in the QoL study must have adequate cognitive ability to complete the QoL questionnaires.
•8. Written informed consent
•Patients may undergo surgical biopsy or non-radical surgery prior to study entry.

•1. Previous radiotherapy to the head and neck region
•2. Clinical evidence of metastatic disease (Stage IVc)
•3. Previous malignancy except non-melanoma skin cancer and early stage cancer in remission for at least 5 years following treatment
•4. Previous or concurrent illness, which in the investigator's opinion would interfere with completion of therapy
•5. Pre-existing previous speech or swallowing problems unrelated to the diagnosis of cancer
•6. Large primary tumour, where organ preservation is unrealistic

发起方

Royal Marsden NHS Foundation Trust (UK)